Hypera SA
BOVESPA:HYPE3

Watchlist Manager
Hypera SA Logo
Hypera SA
BOVESPA:HYPE3
Watchlist
Price: 27.8 BRL 0.98% Market Closed
Market Cap: 17.6B BRL

Net Margin
Hypera SA

12.1%
Current
20%
Average
5.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
12.1%
=
Net Income
808.8m
/
Revenue
6.7B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
BR
Hypera SA
BOVESPA:HYPE3
17.6B BRL
12%
US
Eli Lilly and Co
NYSE:LLY
776.5B USD
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
377.9B USD
24%
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK
35%
CH
Roche Holding AG
SIX:ROG
214.5B CHF
14%
CH
Novartis AG
SIX:NOVN
190.4B CHF
24%
UK
AstraZeneca PLC
LSE:AZN
170.3B GBP
14%
US
Merck & Co Inc
NYSE:MRK
205.6B USD
27%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
-126%
US
Pfizer Inc
NYSE:PFE
139.5B USD
13%

Hypera SA
Glance View

Market Cap
17.6B BRL
Industry
Pharmaceuticals

Hypera S.A., a leading force in the Brazilian pharmaceuticals market, has carved a niche by catering to a wide spectrum of health needs through a diverse portfolio. Originally established under the name Hypermarcas, the company took root with the ambition of becoming a pharmaceutical powerhouse in Brazil. This vision was set in motion through strategic organic growth and a series of savvy acquisitions, which helped consolidate its offerings across over-the-counter (OTC) medications, branded prescriptions, dermo-cosmetics, and generics. Each of these segments represents a cog in the machine that drives Hypera’s profitability, with its robust pipeline of drug innovations and strong brand presence ensuring a steady flow of revenue. What truly sets Hypera apart is its ability to harness the synergies between its diverse product lines and an extensive distribution network across Brazil. The company generates revenue not only by selling pharmaceuticals directly to consumers but also through collaborations with healthcare professionals and pharmacies, ensuring its products reach a vast market. Hypera’s commitment to research and development further fuels its growth engine, as it continuously seeks to introduce new drugs and treatments that meet the evolving healthcare demands. The company’s strategic focus on operational efficiency and cost management underpins its financial performance, while its strong brand recognition makes it a preferred choice among consumers and medical professionals alike in Brazil’s dynamic healthcare environment.

HYPE3 Intrinsic Value
37.2 BRL
Undervaluation 25%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
12.1%
=
Net Income
808.8m
/
Revenue
6.7B
What is the Net Margin of Hypera SA?

Based on Hypera SA's most recent financial statements, the company has Net Margin of 12.1%.

Back to Top